PharmaShots | Incisive News in 3 Shots

Subscribe Now

Forms

Novartis Reports Acceptance of Ofatumumab's (OMB157) sBLA from the US FDA and EMA to Treat Relapsing Forms of Multiple Sclerosis (RMS)

Novartis Reports Acceptance of Ofatumumab's (OMB157) sBLA from the US FDA and EMA to Treat Relapsing Forms of Multiple Sclerosis (...

February 24, 2020

TB Alliance's Pretomanid Combination Therapy Receives the US FDA's Approval for Highly Drug-Resistant Forms of Tuberculosis

TB Alliance's Pretomanid Combination Therapy Receives the US FDA's Approval for Highly Drug-Resistant Forms of Tuberculosis

August 15, 2019

Celgene Reports FDA and EMA's Acceptance of NDA for Ozanimod to Treat Relapsing Forms of Multiple Sclerosis

Celgene Reports FDA and EMA's Acceptance of NDA for Ozanimod to Treat Relapsing Forms of Multiple Sclerosis

June 6, 2019

Novartis' Gilenya (fingolimod) Receives EU's Approval for Relapsing-Remitting Forms of Multiple Sclerosis (RRMS)

Novartis' Gilenya (fingolimod) Receives EU's Approval for Relapsing-Remitting Forms of Multiple Sclerosis (RRMS)

November 30, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us